Boston Scientific Corporation (NYSE:BSX) is one of top cheap stocks with Strong Buy ratings on Wall Street. Boston Scientific Corporation (NYSE:BSX) received a rating update from Canaccord on June 1. The firm lowered the price target on the stock to $70 from $71, reiterating a Buy rating on the shares. Canaccord stated that it updated its model on the stock to take into account slowdowns in the U.S. Watchman business in 2026 and 2027, which have negative implications on its revenue and EPS estimates.
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
Boston Scientific Corporation (NYSE:BSX) also received a rating update from BofA on May 18. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $68 from $105, reaffirming a Buy rating on the shares. The firm told investors that after having hosted 34 medtech companies last week in Las Vegas, it updated several price targets for “the new reality of medtech valuations” in a year of few product cycles, inflation kicking up post-war, ACA, and utilization worries, and “data centers over healthcare”.
Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.
While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.